Aromatase inhibitor-induced modulation of breast density

Clinical and genetic effects

N. L. Henry, H. P. Chan, J. Dantzer, C. P. Goswami, L. Li, Todd Skaar, J. M. Rae, Zeruesenay Desta, N. Khouri, R. Pinsky, S. Oesterreich, C. Zhou, L. Hadjiiski, S. Philips, J. Robarge, A. T. Nguyen, Anna Maria Storniolo, D. A. Flockhart, D. F. Hayes, M. A. Helvie & 1 others V. Stearns

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background:Change in breast density may predict outcome of women receiving adjuvant hormone therapy for breast cancer. We performed a prospective clinical trial to evaluate the impact of inherited variants in genes involved in oestrogen metabolism and signalling on change in mammographic percent density (MPD) with aromatase inhibitor (AI) therapy.Methods:Postmenopausal women with breast cancer who were initiating adjuvant AI therapy were enrolled onto a multicentre, randomised clinical trial of exemestane vs letrozole, designed to identify associations between AI-induced change in MPD and single-nucleotide polymorphisms in candidate genes. Subjects underwent unilateral craniocaudal mammography before and following 24 months of treatment.Results:Of the 503 enrolled subjects, 259 had both paired mammograms at baseline and following 24 months of treatment and evaluable DNA. We observed a statistically significant decrease in mean MPD from 17.1 to 15.1% (P<0.001), more pronounced in women with baseline MPD ≥20%. No AI-specific difference in change in MPD was identified. No significant associations between change in MPD and inherited genetic variants were observed.Conclusion:Subjects with higher baseline MPD had a greater average decrease in MPD with AI therapy. There does not appear to be a substantial effect of inherited variants in biologically selected candidate genes.

Original languageEnglish
Pages (from-to)2331-2339
Number of pages9
JournalBritish Journal of Cancer
Volume109
Issue number9
DOIs
StatePublished - Oct 29 2013

Fingerprint

Aromatase Inhibitors
exemestane
letrozole
Therapeutics
Breast Neoplasms
Genes
Breast Density
Mammography
Single Nucleotide Polymorphism
Estrogens
Randomized Controlled Trials
Clinical Trials
Hormones
DNA

Keywords

  • aromatase inhibitor
  • breast cancer
  • breast density
  • mammogram
  • polymorphism

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Henry, N. L., Chan, H. P., Dantzer, J., Goswami, C. P., Li, L., Skaar, T., ... Stearns, V. (2013). Aromatase inhibitor-induced modulation of breast density: Clinical and genetic effects. British Journal of Cancer, 109(9), 2331-2339. https://doi.org/10.1038/bjc.2013.587

Aromatase inhibitor-induced modulation of breast density : Clinical and genetic effects. / Henry, N. L.; Chan, H. P.; Dantzer, J.; Goswami, C. P.; Li, L.; Skaar, Todd; Rae, J. M.; Desta, Zeruesenay; Khouri, N.; Pinsky, R.; Oesterreich, S.; Zhou, C.; Hadjiiski, L.; Philips, S.; Robarge, J.; Nguyen, A. T.; Storniolo, Anna Maria; Flockhart, D. A.; Hayes, D. F.; Helvie, M. A.; Stearns, V.

In: British Journal of Cancer, Vol. 109, No. 9, 29.10.2013, p. 2331-2339.

Research output: Contribution to journalArticle

Henry, NL, Chan, HP, Dantzer, J, Goswami, CP, Li, L, Skaar, T, Rae, JM, Desta, Z, Khouri, N, Pinsky, R, Oesterreich, S, Zhou, C, Hadjiiski, L, Philips, S, Robarge, J, Nguyen, AT, Storniolo, AM, Flockhart, DA, Hayes, DF, Helvie, MA & Stearns, V 2013, 'Aromatase inhibitor-induced modulation of breast density: Clinical and genetic effects', British Journal of Cancer, vol. 109, no. 9, pp. 2331-2339. https://doi.org/10.1038/bjc.2013.587
Henry, N. L. ; Chan, H. P. ; Dantzer, J. ; Goswami, C. P. ; Li, L. ; Skaar, Todd ; Rae, J. M. ; Desta, Zeruesenay ; Khouri, N. ; Pinsky, R. ; Oesterreich, S. ; Zhou, C. ; Hadjiiski, L. ; Philips, S. ; Robarge, J. ; Nguyen, A. T. ; Storniolo, Anna Maria ; Flockhart, D. A. ; Hayes, D. F. ; Helvie, M. A. ; Stearns, V. / Aromatase inhibitor-induced modulation of breast density : Clinical and genetic effects. In: British Journal of Cancer. 2013 ; Vol. 109, No. 9. pp. 2331-2339.
@article{306c059f8ef244949b8025c2228c808d,
title = "Aromatase inhibitor-induced modulation of breast density: Clinical and genetic effects",
abstract = "Background:Change in breast density may predict outcome of women receiving adjuvant hormone therapy for breast cancer. We performed a prospective clinical trial to evaluate the impact of inherited variants in genes involved in oestrogen metabolism and signalling on change in mammographic percent density (MPD) with aromatase inhibitor (AI) therapy.Methods:Postmenopausal women with breast cancer who were initiating adjuvant AI therapy were enrolled onto a multicentre, randomised clinical trial of exemestane vs letrozole, designed to identify associations between AI-induced change in MPD and single-nucleotide polymorphisms in candidate genes. Subjects underwent unilateral craniocaudal mammography before and following 24 months of treatment.Results:Of the 503 enrolled subjects, 259 had both paired mammograms at baseline and following 24 months of treatment and evaluable DNA. We observed a statistically significant decrease in mean MPD from 17.1 to 15.1{\%} (P<0.001), more pronounced in women with baseline MPD ≥20{\%}. No AI-specific difference in change in MPD was identified. No significant associations between change in MPD and inherited genetic variants were observed.Conclusion:Subjects with higher baseline MPD had a greater average decrease in MPD with AI therapy. There does not appear to be a substantial effect of inherited variants in biologically selected candidate genes.",
keywords = "aromatase inhibitor, breast cancer, breast density, mammogram, polymorphism",
author = "Henry, {N. L.} and Chan, {H. P.} and J. Dantzer and Goswami, {C. P.} and L. Li and Todd Skaar and Rae, {J. M.} and Zeruesenay Desta and N. Khouri and R. Pinsky and S. Oesterreich and C. Zhou and L. Hadjiiski and S. Philips and J. Robarge and Nguyen, {A. T.} and Storniolo, {Anna Maria} and Flockhart, {D. A.} and Hayes, {D. F.} and Helvie, {M. A.} and V. Stearns",
year = "2013",
month = "10",
day = "29",
doi = "10.1038/bjc.2013.587",
language = "English",
volume = "109",
pages = "2331--2339",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Aromatase inhibitor-induced modulation of breast density

T2 - Clinical and genetic effects

AU - Henry, N. L.

AU - Chan, H. P.

AU - Dantzer, J.

AU - Goswami, C. P.

AU - Li, L.

AU - Skaar, Todd

AU - Rae, J. M.

AU - Desta, Zeruesenay

AU - Khouri, N.

AU - Pinsky, R.

AU - Oesterreich, S.

AU - Zhou, C.

AU - Hadjiiski, L.

AU - Philips, S.

AU - Robarge, J.

AU - Nguyen, A. T.

AU - Storniolo, Anna Maria

AU - Flockhart, D. A.

AU - Hayes, D. F.

AU - Helvie, M. A.

AU - Stearns, V.

PY - 2013/10/29

Y1 - 2013/10/29

N2 - Background:Change in breast density may predict outcome of women receiving adjuvant hormone therapy for breast cancer. We performed a prospective clinical trial to evaluate the impact of inherited variants in genes involved in oestrogen metabolism and signalling on change in mammographic percent density (MPD) with aromatase inhibitor (AI) therapy.Methods:Postmenopausal women with breast cancer who were initiating adjuvant AI therapy were enrolled onto a multicentre, randomised clinical trial of exemestane vs letrozole, designed to identify associations between AI-induced change in MPD and single-nucleotide polymorphisms in candidate genes. Subjects underwent unilateral craniocaudal mammography before and following 24 months of treatment.Results:Of the 503 enrolled subjects, 259 had both paired mammograms at baseline and following 24 months of treatment and evaluable DNA. We observed a statistically significant decrease in mean MPD from 17.1 to 15.1% (P<0.001), more pronounced in women with baseline MPD ≥20%. No AI-specific difference in change in MPD was identified. No significant associations between change in MPD and inherited genetic variants were observed.Conclusion:Subjects with higher baseline MPD had a greater average decrease in MPD with AI therapy. There does not appear to be a substantial effect of inherited variants in biologically selected candidate genes.

AB - Background:Change in breast density may predict outcome of women receiving adjuvant hormone therapy for breast cancer. We performed a prospective clinical trial to evaluate the impact of inherited variants in genes involved in oestrogen metabolism and signalling on change in mammographic percent density (MPD) with aromatase inhibitor (AI) therapy.Methods:Postmenopausal women with breast cancer who were initiating adjuvant AI therapy were enrolled onto a multicentre, randomised clinical trial of exemestane vs letrozole, designed to identify associations between AI-induced change in MPD and single-nucleotide polymorphisms in candidate genes. Subjects underwent unilateral craniocaudal mammography before and following 24 months of treatment.Results:Of the 503 enrolled subjects, 259 had both paired mammograms at baseline and following 24 months of treatment and evaluable DNA. We observed a statistically significant decrease in mean MPD from 17.1 to 15.1% (P<0.001), more pronounced in women with baseline MPD ≥20%. No AI-specific difference in change in MPD was identified. No significant associations between change in MPD and inherited genetic variants were observed.Conclusion:Subjects with higher baseline MPD had a greater average decrease in MPD with AI therapy. There does not appear to be a substantial effect of inherited variants in biologically selected candidate genes.

KW - aromatase inhibitor

KW - breast cancer

KW - breast density

KW - mammogram

KW - polymorphism

UR - http://www.scopus.com/inward/record.url?scp=84887022249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887022249&partnerID=8YFLogxK

U2 - 10.1038/bjc.2013.587

DO - 10.1038/bjc.2013.587

M3 - Article

VL - 109

SP - 2331

EP - 2339

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 9

ER -